{"entity":{"id":"plx-61639","kind":"drug","name":"PLX-61639","aka":[],"tldr":"PLX-61639 is an experimental oral monovalent direct protein degrader from Plexium, in phase 1 trials for SMARCA4-mutant locally advanced or metastatic solid tumours, non-small cell lung cancer and oesophageal and gastric cancers.","summary":"PLX-61639 is an oral monovalent direct protein degrader from Plexium. An oral SMARCA2-selective degrader that uses a tissue-restricted E3 ligase; tumours that have lost SMARCA4 depend on SMARCA2, so removing it is synthetically lethal for them. Its furthest stage is phase 1, for SMARCA4-mutant locally advanced or metastatic solid tumours, non-small cell lung cancer and oesophageal and gastric cancers. ClinicalTrials.gov registers it in one study linked below. First-in-human phase 1 recruiting (NCT07284186). Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"Plexium: plexium.com","url":"https://plexium.com/pipeline/"},{"label":"Plexium: plexium.com","url":"https://plexium.com/clinical-trials/"},{"label":"Plexium: clinicaltrials.gov","url":"https://clinicaltrials.gov/study/NCT07284186"},{"label":"ClinicalTrials.gov: trials of PLX-61639","url":"https://clinicaltrials.gov/search?intr=PLX-61639"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer","nsclc","gastric"],"sections":[],"technologies":[],"targets":["smarca2"],"drugs":[],"companies":["plexium"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07284186"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"PLX-61639","modality":"Oral monovalent direct protein degrader","mechanism":"An oral SMARCA2-selective degrader that uses a tissue-restricted E3 ligase; tumours that have lost SMARCA4 depend on SMARCA2, so removing it is synthetically lethal for them.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/plx-61639/","neighbours":{"cancer":[{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"},{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"target":[{"id":"smarca2","kind":"target","name":"SMARCA2","route":"/targets/smarca2/"}],"company":[{"id":"plexium","kind":"company","name":"Plexium","route":"/companies/plexium/"}],"trial":[{"id":"nct07284186","kind":"trial","name":"First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors","route":"/trials/nct07284186/"}]}}